Neuroscience and Behavioral Physiology

, Volume 46, Issue 5, pp 539–543 | Cite as

Models for Evaluating Therapeutic Resistance of Depression

  • G. E. Mazo
  • N. G. Neznanov
  • A. S. Krizhanovskii

We present a review of existing models for evaluating treatment-resistant depression (TRD). Their main advantages and drawbacks are identified, and the potential for using them in clinical practice is assessed. A new spectral model of TRD is presented, which considers the clinical spectrum of types (variants) of TRD; this model requires further development.


depression therapeutic resistance evaluation models 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. H. Kennedy, R. W. Lam, D. J. Nutt, and M. E. Thase, Treating Depression Effectively: Applying Clinical Guidelines, London 2004.Google Scholar
  2. 2.
    M. Fava, “Diagnosis and definition of treatment-resistant depression,” Biol. Psychiatry, 53, No. 8, 649–659 (2003).CrossRefPubMedGoogle Scholar
  3. 3.
    A. J. Rush, M. H. Trivedi, S. R. Wisniewski, et al., “Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report,” Am. J. Psychiatry, 163, No. 11, 1905–1917 (2006).CrossRefPubMedGoogle Scholar
  4. 4.
    F. Ayd, “Treatment resistant depression,” Int. Drug Newsletter, 18, 23–27 (1983).Google Scholar
  5. 5.
    M. T. Berlim and G. Turecki, “Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods,” Can. J. Psychiatry, 52, No. 1, 46–54 (2007).PubMedGoogle Scholar
  6. 6.
    C. B. Nemeroff, “Prevalence and management of treatment-resistant depression,” J. Clin. Psychiatry, 68, Suppl. 8, 17–25 (2007).PubMedGoogle Scholar
  7. 7.
    Committee for Medicinal Products for Human Use (CHMP), Concept Paper on the Need for Revision of Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression with regard to Treatment Resistant Depression, European Medicines Agency, London (2009).Google Scholar
  8. 8.
    R. Ya. Vovin and I. O. Aksenova, Chronic Depressive States, Meditsina, Leningrad (1982).Google Scholar
  9. 9.
    M. E. Thase and A. J. Rush, “When at first you don’t succeed: sequential strategies for antidepressant nonresponders,” J. Clin. Psychiatry, 58, Suppl. 13, 23–29 (1997).PubMedGoogle Scholar
  10. 10.
    S. N. Mosolov, The Clinical Use of Contemporary Antidepressants, MIA, St. Petersburg (1995).Google Scholar
  11. 11.
    I. M. Anderson, D. J. Nutt, and J. F. W. Deakin, “Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology Guidelines,” J. Psychopharmacol., 14, No. 1, 3–20 (2000).CrossRefPubMedGoogle Scholar
  12. 12.
    R. W. Lam, S. H. Kennedy, S. Grigoriadis, et al., “ Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy,” J. Affect. Disord., 117, Suppl. 1, 26–43 (2009).CrossRefGoogle Scholar
  13. 13.
    NICE, Clinical Guideline 23. Depression: Management of Depression in Primary and Secondary Care, National Institute for Clinical Excellence, London (2007).Google Scholar
  14. 14.
    D. Souery, G. I. Papakostas, and M. H. Trivedi, “Treatment-resistant depression,” J. Clin. Psychiatry, 67, Suppl. 6, 16–22 (2006).PubMedGoogle Scholar
  15. 15.
    M. E. Thase, A. R. Entsuah, and R. L. Rudolph, “Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors,” Brit. J. Psychiatry, 178, 234–241 (2001).CrossRefGoogle Scholar
  16. 16.
    S. Mace and D. Taylor, “Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression,” Expert Opin. Pharmacother., 1, No. 5, 917–933 (2000).CrossRefPubMedGoogle Scholar
  17. 17.
    M. E. Thase, A. J. Rush, R. H. Howland, et al., “Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression,” Arch. Gen. Psychiatry, 59, No. 3, 233–239 (2002).CrossRefPubMedGoogle Scholar
  18. 18.
    J. Spijker and W. A. Nolen, “An algorithm for the pharmacological treatment of depression,” Acta Psychiatr. Scand., 121, No. 3, 1809–189 (2010).CrossRefGoogle Scholar
  19. 19.
    D. Souery, J. Amsterdam, C. de Montigny, et al., “Treatment resistant depression: methodological overview and operational criteria,” Eur. Neuropsychopharmacol., 9, No. 1–2, 83–91 (1999).CrossRefPubMedGoogle Scholar
  20. 20.
    H. G. Ruhe, J. Huyser, J. A. Swinkels, and A. H. Schene, “Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review,” J. Clin. Psychiatry, 67, No. 12, 1836–1855 (2006).CrossRefPubMedGoogle Scholar
  21. 21.
    A. Fekadu, S. Wooderson, C. Donaldson, et al., “A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method,” J. Clin. Psychiatry, 70, No. 2, 177–184 (2009).CrossRefPubMedGoogle Scholar
  22. 22.
    H. G. Ruhe, J. Booij, H. C. Weert, et al., “Evidence why dose-escalation of paroxetine in major depressive disorder is not effective: a 6-week, randomized-controlled trial with assessment of serotonin transporter occupancy,” Neuropsychopharmacology, 34, 999–1010 (2009).CrossRefPubMedGoogle Scholar
  23. 23.
    H. G. Ruhe, J. Huyser, J. A. Swinkels, and A. H. Schene, “Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review,” Brit. J. Psychiatry, 189, 309–316 (2006).CrossRefGoogle Scholar
  24. 24.
    M. H. Trivedi, M. Fava, S. R. Wisniewski, et al., “Medication augmentation after the failure of SSRIs for depression,” N. Eng. J. Med., 354, No. 12, 1243–1252 (2006).CrossRefGoogle Scholar
  25. 25.
    S. E. Hetrick, A. G. Parker, I. B. Hickie, et al., “Early identification and intervention in depressive disorders: towards a clinical staging model,” Psychother. Psychosom., 77, No. 5, 263–270 (2008).CrossRefPubMedGoogle Scholar
  26. 26.
    D. Souery, P. Oswald, I. Massat, et al., “Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study,” J. Clin. Psychiatry, 68, No. 7, 1062–1070 (2007).CrossRefPubMedGoogle Scholar
  27. 27.
    G. Andrews and R. Jenkins, Management of Mental Disorders, World Health Organization Collaborating Centre in Mental Health, London (1999).Google Scholar
  28. 28.
    M. B. Blom, P. Spinhoven, T. Hoffman, et al., “Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression,” J. Affect. Disord., 104, No. 1–3, 119–126 (2007).CrossRefPubMedGoogle Scholar
  29. 29.
    W. Katon, E. Lin, M. von Korff, et al., “The predictors of persistence of depression in primary care,” J. Affect. Disord., 31, No. 2, 81–90 (1994).CrossRefPubMedGoogle Scholar
  30. 30.
    P. J. McGrath, J. W. Stewart, F. M. Quitkin, et al., “Predictors of relapse in a prospective study of fl uoxetine treatment of major depression,” Am. J. Psychiatry, 163, No. 9, 1542–1548 (2006).CrossRefPubMedGoogle Scholar
  31. 31.
    P. B. Mitchell, I. Schweitzer, G. Burrows, et al., “Efficacy of venlafaxine and predictors of response in a prospective open label study of patients with treatment-resistant major depression,” J. Clin. Psychopharmacol., 20, No. 4, 483–487 (2000).CrossRefPubMedGoogle Scholar
  32. 32.
    J. Prudic, R. F. Haskett, B. Mulsant, et al., “Resistance to antidepressant medications and short-term clinical response to ECT,” Am. J. Psychiatry, 153, No. 8, 985–992 (1996).CrossRefPubMedGoogle Scholar
  33. 33.
    L. V. Rubenstein, N. R. Rayburn, E. B. Keeler, et al., “Predicting outcomes of primary care patients with major depression: development of a depression prognosis index,” Psychiatr. Serv., 58, No. 8, 1049–1056 (2007).CrossRefPubMedGoogle Scholar
  34. 34.
    U. Halbreich, “Major depression is not a diagnosis; it is a departure point to differential diagnosis – clinical and hormonal considerations (A commentary and elaboration on Antonijevic’s paper),” Psychoneuro endocrinology, 31, 16–22 (2006).CrossRefGoogle Scholar
  35. 35.
    I. A. Antonijevic, “Depressive disorders – Is it time to endorse different pathophysiologies?” Psychoneuroendocrinology, 31, No. 1, 1–15 (2006).Google Scholar
  36. 36.
    N. G. Neznanov, G. E. Mazo, S. N. Kozlova, and A. S. Krizhanovskii, “From the development of endophenomenological classification of depression to the different prescription of antidepressant treatment,” Sovrem. Ter. Psikikh. Rasstr., No. 4, 1–7 (2013).Google Scholar
  37. 37.
    G. E. Mazo and N. G. Neznanov, Treatment-Resistant Depression, St. Petersburg (2012).Google Scholar
  38. 38.
    S. N. Mosolov, Biological Methods for the Treatment of Mental Disorders (evidence-based medicine – clinical practice), Moscow (2012).Google Scholar
  39. 39.
    H. Baumeister and G. Parker, “Meta-review of depressive subtyping models,” J. Affect Disord., 139, 126–140 (2012).CrossRefGoogle Scholar
  40. 40.
    T. Eller, V. Vasar, J. Slik and E. Maron, “Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, No. 2, 445–450 (2008).CrossRefPubMedGoogle Scholar
  41. 41.
    G. Malhi, G. Parker, and J. Greenwood, “Structural and functional models of depression: from sub-types to substrates,” Acta Psychiatr. Scand., 111, 94–105 (2005).CrossRefPubMedGoogle Scholar
  42. 42.
    L. Rayner, A. Price, A. Evans, et al., “Antidepressants for depression in physically ill people,” Cochrane Database Syst. Rev., No. 3 CD007503, (2010).Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • G. E. Mazo
    • 1
  • N. G. Neznanov
    • 1
  • A. S. Krizhanovskii
    • 1
  1. 1.St. Petersburg Research Psychoneurological InstituteSt. PetersburgRussia

Personalised recommendations